{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:29:36Z","timestamp":1792175376568,"version":"4.4.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-025-00586-7","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T04:04:13Z","timestamp":1770177853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Plant-derived compounds as potential candidates for atrial fibrillation drug discovery: A review on phytochemicals with atrial-selective activity"],"prefix":"10.1007","volume":"34","author":[{"given":"Bayan","family":"Azizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danesh","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arian","family":"Tavasol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Hojjatifard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouria","family":"Delbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Firoozbakhsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roja","family":"Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Vasheghani-Farahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"issue":"3","key":"586_CR1","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/europace\/euac237","volume":"25","author":"XJ Dong","year":"2023","unstructured":"Dong XJ, Wang BB, Hou FF, et al. Global burden of atrial fibrillation\/atrial flutter and its attributable risk factors from 1990 to 2019. Europace. 2023;25(3):793\u2013803. https:\/\/doi.org\/10.1093\/europace\/euac237.","journal-title":"Europace"},{"issue":"14","key":"586_CR2","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1177\/2047487317715769","volume":"24","author":"V Ruddox","year":"2017","unstructured":"Ruddox V, Sandven I, Munkhaugen J, et al. Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24(14):1555\u201366. https:\/\/doi.org\/10.1177\/2047487317715769.","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"586_CR3","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/s0002-9343(02)01236-6","volume":"113","author":"S Stewart","year":"2002","unstructured":"Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew\/Paisley study. Am J Med. 2002;113(5):359\u201364. https:\/\/doi.org\/10.1016\/s0002-9343(02)01236-6.","journal-title":"Am J Med"},{"key":"586_CR4","doi-asserted-by":"publisher","first-page":"581837","DOI":"10.3389\/fphar.2020.581837","volume":"11","author":"M Geng","year":"2020","unstructured":"Geng M, Lin A, Nguyen TP. Revisiting antiarrhythmic drug therapy for atrial fibrillation: reviewing lessons learned and redefining therapeutic paradigms. Front Pharmacol. 2020;11:581837. https:\/\/doi.org\/10.3389\/fphar.2020.581837.","journal-title":"Front Pharmacol"},{"issue":"1","key":"586_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/10408398.2017.1360244","volume":"59","author":"R Bahramsoltani","year":"2019","unstructured":"Bahramsoltani R, Ebrahimi F, Farzaei MH, et al. Dietary polyphenols for atherosclerosis: A comprehensive review and future perspectives. Crit Rev Food Sci Nutr. 2019;59(1):114\u201332. https:\/\/doi.org\/10.1080\/10408398.2017.1360244.","journal-title":"Crit Rev Food Sci Nutr"},{"key":"586_CR6","doi-asserted-by":"publisher","first-page":"990063","DOI":"10.3389\/fcvm.2022.990063","volume":"9","author":"D Soltani","year":"2022","unstructured":"Soltani D, Azizi B, Rahimi R, et al. Mechanism-based targeting of cardiac arrhythmias by phytochemicals and medicinal herbs: a comprehensive review of preclinical and clinical evidence. Front Cardiovasc Med. 2022;9:990063. https:\/\/doi.org\/10.3389\/fcvm.2022.990063.","journal-title":"Front Cardiovasc Med"},{"issue":"33","key":"586_CR7","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1093\/eurheartj\/ehz583","volume":"40","author":"H Tavolinejad","year":"2019","unstructured":"Tavolinejad H, Soltani D, Zargaran A, et al. The story of Amiodarone. Eur Heart J. 2019;40(33):2758\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehz583.","journal-title":"Eur Heart J"},{"issue":"4","key":"586_CR8","doi-asserted-by":"publisher","first-page":"587","DOI":"10.15446\/revfacmed.v62n4.44015","volume":"62","author":"HH Le\u00f3n Ariza","year":"2015","unstructured":"Le\u00f3n Ariza HH, Valenzuela Faccini N, Rojas Ortega AC, et al. Nav1.5 cardiac sodium channels, regulation and clinical implications. Revista De La Facultad De Med. 2015;62(4):587\u201392. https:\/\/doi.org\/10.15446\/revfacmed.v62n4.44015.","journal-title":"Revista De La Facultad De Med"},{"issue":"3","key":"586_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/gb-2003-4-3-207","volume":"4","author":"FH Yu","year":"2003","unstructured":"Yu FH, Catterall WA. Overview of the voltage-gated sodium channel family. Genome Biol. 2003;4(3):207. https:\/\/doi.org\/10.1186\/gb-2003-4-3-207.","journal-title":"Genome Biol"},{"issue":"2","key":"586_CR10","first-page":"125","volume":"21","author":"S Arora","year":"2005","unstructured":"Arora S, Mahajan B, Gupta K, et al. Voltage-gated sodium channels: physiology, pathology and therapeutic potential. J Anaesthesiol Clin Pharmacol. 2005;21(2):125\u201336.","journal-title":"J Anaesthesiol Clin Pharmacol"},{"issue":"2","key":"586_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1085\/jgp.201311046","volume":"142","author":"CA Ahern","year":"2013","unstructured":"Ahern CA. What activates inactivation? J Gen Physiol. 2013;142(2):97\u2013100. https:\/\/doi.org\/10.1085\/jgp.201311046.","journal-title":"J Gen Physiol"},{"issue":"3","key":"586_CR12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cardiores.2007.07.019","volume":"76","author":"H Abriel","year":"2007","unstructured":"Abriel H. Roles and regulation of the cardiac sodium channel Na v 1.5: recent insights from experimental studies. Cardiovasc Res. 2007;76(3):381\u20139. https:\/\/doi.org\/10.1016\/j.cardiores.2007.07.019.","journal-title":"Cardiovasc Res"},{"key":"586_CR13","first-page":"287","volume-title":"Current topics in membranes","author":"K DeMarco","year":"2016","unstructured":"DeMarco K, Clancy C. Cardiac Na channels: structure to function. In: Current topics in membranes. Elsevier; 2016. p. 287\u2013311."},{"issue":"13","key":"586_CR14","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1161\/CIRCULATIONAHA.107.704890","volume":"116","author":"A Burashnikov","year":"2007","unstructured":"Burashnikov A, Di Diego JM, Zygmunt AC, et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of Ranolazine. Circulation. 2007;116(13):1449\u201357. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.704890.","journal-title":"Circulation"},{"issue":"2","key":"586_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1517\/14728210902997939","volume":"14","author":"A Burashnikov","year":"2009","unstructured":"Burashnikov A, Antzelevitch C. Atrial-selective sodium channel block for the treatment of atrial fibrillation. Expert Opin Emerg Drugs. 2009;14(2):233\u201349. https:\/\/doi.org\/10.1517\/14728210902997939.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"586_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10557-012-6421-1","volume":"27","author":"A Burashnikov","year":"2013","unstructured":"Burashnikov A, Antzelevitch C. Role of late sodium channel current block in the management of atrial fibrillation. Cardiovasc Drugs Ther. 2013;27(1):79\u201389. https:\/\/doi.org\/10.1007\/s10557-012-6421-1.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"586_CR17","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/ajcn\/76.3.560","volume":"76","author":"P Knekt","year":"2002","unstructured":"Knekt P, Kumpulainen J, Jarvinen R, et al. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr. 2002;76(3):560\u20138. https:\/\/doi.org\/10.1093\/ajcn\/76.3.560.","journal-title":"Am J Clin Nutr"},{"issue":"12","key":"586_CR18","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/aps.2016.97","volume":"37","author":"H Wang","year":"2016","unstructured":"Wang H, Wang HF, Zhang H, et al. Inhibitory effects of Hesperetin on Nav1.5 channels stably expressed in HEK 293 cells and on the voltage-gated cardiac sodium current in human atrial myocytes. Acta Pharmacol Sin. 2016;37(12):1563\u201373. https:\/\/doi.org\/10.1038\/aps.2016.97.","journal-title":"Acta Pharmacol Sin"},{"key":"586_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fphar.2013.00078","volume":"4","author":"S Sokolov","year":"2013","unstructured":"Sokolov S, Peters CH, Rajamani S, et al. Proton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazine. Front Pharmacol. 2013;4:78. https:\/\/doi.org\/10.3389\/fphar.2013.00078.","journal-title":"Front Pharmacol"},{"issue":"6","key":"586_CR20","doi-asserted-by":"publisher","first-page":"e0128653","DOI":"10.1371\/journal.pone.0128653","volume":"10","author":"Y Wang","year":"2015","unstructured":"Wang Y, Mi J, Lu K, et al. Comparison of gating properties and use-dependent block of Nav1.5 and Nav1.7 channels by anti-arrhythmics mexiletine and lidocaine. PLoS One. 2015;10(6):e0128653. https:\/\/doi.org\/10.1371\/journal.pone.0128653.","journal-title":"PLoS One"},{"issue":"2","key":"586_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1691\/ph.2011.0744","volume":"66","author":"L Huang","year":"2011","unstructured":"Huang L, Zhao H, Huang B, et al. Acanthopanax senticosus: review of botany, chemistry and Pharmacology. Pharmazie. 2011;66(2):83\u201397. https:\/\/doi.org\/10.1691\/ph.2011.0744.","journal-title":"Pharmazie"},{"issue":"2","key":"586_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41401-020-0453-z","volume":"42","author":"PP Zhang","year":"2021","unstructured":"Zhang PP, Guo ZF, Zhang PH, et al. Eleutheroside B, a selective late sodium current inhibitor, suppresses atrial fibrillation induced by sea anemone toxin II in rabbit hearts. Acta Pharmacol Sin. 2021;42(2):209\u201317. https:\/\/doi.org\/10.1038\/s41401-020-0453-z.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"586_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.hrthm.2016.10.008","volume":"14","author":"M Gong","year":"2017","unstructured":"Gong M, Zhang Z, Fragakis N, et al. Role of ranolazine in the prevention and treatment of atrial fibrillation: a meta-analysis of randomized clinical trials. Heart Rhythm. 2017;14(1):3\u201311. https:\/\/doi.org\/10.1016\/j.hrthm.2016.10.008.","journal-title":"Heart Rhythm"},{"issue":"5","key":"586_CR24","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.hrthm.2015.01.021","volume":"12","author":"GM De Ferrari","year":"2015","unstructured":"De Ferrari GM, Maier LS, Mont L, et al. Ranolazine in the treatment of atrial fibrillation: results of the dose-ranging RAFFAELLO (ranolazine in atrial fibrillation following an electrical cardioversion) study. Heart Rhythm. 2015;12(5):872\u20138. https:\/\/doi.org\/10.1016\/j.hrthm.2015.01.021.","journal-title":"Heart Rhythm"},{"issue":"2","key":"586_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/cpt.205","volume":"99","author":"L Johannesen","year":"2016","unstructured":"Johannesen L, Vicente J, Mason JW, et al. Late sodium current block for drug-induced long QT syndrome: results from a prospective clinical trial. Clin Pharmacol Ther. 2016;99(2):214\u201323. https:\/\/doi.org\/10.1002\/cpt.205.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"586_CR26","doi-asserted-by":"publisher","first-page":"996","DOI":"10.2174\/1389203720666190807123609","volume":"20","author":"J Li","year":"2019","unstructured":"Li J, Li B, Huang H, et al. Allocryptopine: A review of its properties and mechanism of antiarrhythmic effect. Curr Protein Pept Sci. 2019;20(10):996\u20131003. https:\/\/doi.org\/10.2174\/1389203720666190807123609.","journal-title":"Curr Protein Pept Sci"},{"issue":"2","key":"586_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.5830\/CVJA-2018-072","volume":"30","author":"Y Dong","year":"2019","unstructured":"Dong Y, Huang Y, Wu HL, et al. Change in late sodium current of atrial myocytes in spontaneously hypertensive rats with allocryptopine treatment. Cardiovasc J Afr. 2019;30(2):79\u201386. https:\/\/doi.org\/10.5830\/CVJA-2018-072.","journal-title":"Cardiovasc J Afr"},{"issue":"2","key":"586_CR28","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1159\/000430134","volume":"36","author":"HJ Wu","year":"2015","unstructured":"Wu HJ, Yang JY, Jin M, et al. Glycyrrhetinic acid protects the heart from ischemia\/reperfusion injury by attenuating the susceptibility and incidence of fatal ventricular arrhythmia during the reperfusion period in the rat hearts. Cell Physiol Biochem. 2015;36(2):741\u201352. https:\/\/doi.org\/10.1159\/000430134.","journal-title":"Cell Physiol Biochem"},{"key":"586_CR29","doi-asserted-by":"publisher","unstructured":"Du YM, Xia CK, Zhao N et al. 18beta-Glycyrrhetinic acid preferentially blocks late Na current generated by DeltaKPQ Nav1.5 channels. Acta Pharmacol Sin, 2012. 33(6): 752\u201360 https:\/\/doi.org\/10.1038\/aps.2012.22","DOI":"10.1038\/aps.2012.22"},{"issue":"3","key":"586_CR30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/bph.16228","volume":"181","author":"IS Chen","year":"2024","unstructured":"Chen IS, Yasuda J, Notomi T, et al. Licorice metabolite 18beta-glycyrrhetinic acid activates G protein-gated inwardly rectifying K(+) channels. Br J Pharmacol. 2024;181(3):447\u201363. https:\/\/doi.org\/10.1111\/bph.16228.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"586_CR31","doi-asserted-by":"publisher","first-page":"e14448","DOI":"10.1111\/cbdd.14448","volume":"103","author":"H Liang","year":"2024","unstructured":"Liang H, Zhang N, Zhao L, et al. Glycyrrhetinic acid alleviates atrial fibrillation by inhibiting the expression of PIM1. Chem Biol Drug Des. 2024;103(2):e14448. https:\/\/doi.org\/10.1111\/cbdd.14448.","journal-title":"Chem Biol Drug Des"},{"issue":"1","key":"586_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/nyas.12843","volume":"1348","author":"I Baczko","year":"2015","unstructured":"Baczko I, Light PE. Resveratrol and derivatives for the treatment of atrial fibrillation. Ann N Y Acad Sci. 2015;1348(1):68\u201374. https:\/\/doi.org\/10.1111\/nyas.12843.","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"586_CR33","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/sj.bjp.0706897","volume":"149","author":"CH Wallace","year":"2006","unstructured":"Wallace CH, Baczko I, Jones L, et al. Inhibition of cardiac voltage-gated sodium channels by grape polyphenols. Br J Pharmacol. 2006;149(6):657\u201365. https:\/\/doi.org\/10.1038\/sj.bjp.0706897.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"586_CR34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/bph.12409","volume":"171","author":"I Baczko","year":"2014","unstructured":"Baczko I, Liknes D, Yang W, et al. Characterization of a novel multifunctional Resveratrol derivative for the treatment of atrial fibrillation. Br J Pharmacol. 2014;171(1):92\u2013106. https:\/\/doi.org\/10.1111\/bph.12409.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"586_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.hrthm.2011.08.027","volume":"9","author":"A Burashnikov","year":"2012","unstructured":"Burashnikov A, Petroski A, Hu D, et al. Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation. Heart Rhythm. 2012;9(1):125\u201331. https:\/\/doi.org\/10.1016\/j.hrthm.2011.08.027.","journal-title":"Heart Rhythm"},{"key":"586_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/DDDT.S485723","volume":"19","author":"W Xie","year":"2025","unstructured":"Xie W, Gao J, Liang Y, et al. Identification of lauric acid as a potent sodium channel Na(V)1.5 blocker from compound Chinese medicine Wenxin Keli. Drug Des Devel Ther. 2025;19:141\u201357. https:\/\/doi.org\/10.2147\/DDDT.S485723.","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"586_CR37","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jacc.2007.08.067","volume":"51","author":"JR Ehrlich","year":"2008","unstructured":"Ehrlich JR, Biliczki P, Hohnloser SH, et al. Atrial-selective approaches for the treatment of atrial fibrillation. J Am Coll Cardiol. 2008;51(8):787\u201392. https:\/\/doi.org\/10.1016\/j.jacc.2007.08.067.","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"586_CR38","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1113\/jphysiol.2013.256115","volume":"591","author":"U Ravens","year":"2013","unstructured":"Ravens U, Poulet C, Wettwer E, et al. Atrial selectivity of antiarrhythmic drugs. J Physiol. 2013;591(17):4087\u201397. https:\/\/doi.org\/10.1113\/jphysiol.2013.256115.","journal-title":"J Physiol"},{"issue":"Pt 1","key":"586_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1113\/jphysiol.1996.sp021194","volume":"491","author":"GJ Amos","year":"1996","unstructured":"Amos GJ, Wettwer E, Metzger F, et al. Differences between outward currents of human atrial and subepicardial ventricular myocytes. J Physiol. 1996;491(Pt 1):31\u201350. https:\/\/doi.org\/10.1113\/jphysiol.1996.sp021194.","journal-title":"J Physiol"},{"issue":"23","key":"586_CR40","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1161\/CIRCULATIONAHA.115.018016","volume":"132","author":"M Aguilar","year":"2015","unstructured":"Aguilar M, Xiong F, Qi XY, et al. Potassium channel blockade enhances atrial fibrillation-selective antiarrhythmic effects of optimized state-dependent sodium channel blockade. Circulation. 2015;132(23):2203\u201311. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018016.","journal-title":"Circulation"},{"issue":"19","key":"586_CR41","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1161\/CIRCULATIONAHA.108.769554","volume":"117","author":"GR Li","year":"2008","unstructured":"Li GR, Wang HB, Qin GW, et al. Acacetin, a natural flavone, selectively inhibits human atrial repolarization potassium currents and prevents atrial fibrillation in dogs. Circulation. 2008;117(19):2449\u201357. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.769554.","journal-title":"Circulation"},{"issue":"2","key":"586_CR42","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/(SICI)1098-2299(199610)39:2<138::AID-DDR5>3.0.CO;2-Q","volume":"39","author":"DZ Dai","year":"1996","unstructured":"Dai DZ, Yu F, Li HT, et al. Blockade on sodium, potassium, and calcium channels by a new antiarrhythmic agent CPU 86017. Drug Dev Res. 1996;39(2):138\u201346. Doi 10.1002\/(Sici)1098\u20132299(199610)39:2\u2009<\u2009138::Aid-Ddr5\u2009>\u20093.0.Co;2-Q.","journal-title":"Drug Dev Res"},{"issue":"3","key":"586_CR43","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3724\/sp.J.1009.2010.00212","volume":"8","author":"Y-Q Tang","year":"2010","unstructured":"Tang Y-Q, Guo X, Chen C-L, et al. Effects of Berberine derivate CPU 86017 on IKur currents and experimental atrial fibrillation. Chin J Nat Med. 2010;8(3):212\u20137. https:\/\/doi.org\/10.3724\/sp.J.1009.2010.00212.","journal-title":"Chin J Nat Med"},{"issue":"3","key":"586_CR44","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/BF02977790","volume":"28","author":"JS Eun","year":"2005","unstructured":"Eun JS, Choi BH, Park JA, et al. Open channel block of hKv1.5 by psoralen from heracleum moellendorffii hance. Arch Pharm Res. 2005;28(3):269\u201373. https:\/\/doi.org\/10.1007\/BF02977790.","journal-title":"Arch Pharm Res"},{"issue":"4","key":"586_CR45","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1248\/bpb.28.657","volume":"28","author":"JS Eun","year":"2005","unstructured":"Eun JS, Park JA, Choi BH, et al. Effects of Oxypeucedanin on hKv1.5 and action potential duration. Biol Pharm Bull. 2005;28(4):657\u201360. https:\/\/doi.org\/10.1248\/bpb.28.657.","journal-title":"Biol Pharm Bull"},{"issue":"10","key":"586_CR46","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1007\/BF02973902","volume":"29","author":"YG Kwak","year":"2006","unstructured":"Kwak YG, Kim DK, Ma TZ, et al. Torilin from Torilis japonica (Houtt.) DC. blocks hKv1.5 channel current. Arch Pharm Res. 2006;29(10):834\u20139. https:\/\/doi.org\/10.1007\/BF02973902.","journal-title":"Arch Pharm Res"},{"key":"586_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2021.114168","volume":"276","author":"X Liu","year":"2021","unstructured":"Liu X, Duan X, Fan H, et al. 8-hydroxypinoresinol-4-O-\u03b2-D-glucoside from Valeriana officinalis L. is a novel Kv1.5 channel blocker. J Ethnopharmacol. 2021;276:114168. https:\/\/doi.org\/10.1016\/j.jep.2021.114168.","journal-title":"J Ethnopharmacol"},{"issue":"4","key":"586_CR48","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0031-6997(24)01385-1","volume":"50","author":"M Yamada","year":"1998","unstructured":"Yamada M, Inanobe A, Kurachi Y. G protein regulation of potassium ion channels. Pharmacol Rev. 1998;50(4):723\u201360.","journal-title":"Pharmacol Rev"},{"issue":"10","key":"586_CR49","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1177\/002215540104901004","volume":"49","author":"H Dobrzynski","year":"2001","unstructured":"Dobrzynski H, Marples DD, Musa H, et al. Distribution of the muscarinic K\u2009+\u2009channel proteins Kir3.1 and Kir3.4 in the ventricle, atrium, and sinoatrial node of heart. J Histochem Cytochem. 2001;49(10):1221\u201334. https:\/\/doi.org\/10.1177\/002215540104901004.","journal-title":"J Histochem Cytochem"},{"issue":"8","key":"586_CR50","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/s0735-1097(01)01304-3","volume":"37","author":"P Kovoor","year":"2001","unstructured":"Kovoor P, Wickman K, Maguire CT, et al. Evaluation of the role of I(KACh) in atrial fibrillation using a mouse knockout model. J Am Coll Cardiol. 2001;37(8):2136\u201343. https:\/\/doi.org\/10.1016\/s0735-1097(01)01304-3.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"586_CR51","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1161\/hc4601.099466","volume":"104","author":"D Dobrev","year":"2001","unstructured":"Dobrev D, Graf E, Wettwer E, et al. Molecular basis of downregulation of G-protein-coupled inward rectifying K(+) current (I(K,ACh) in chronic human atrial fibrillation: decrease in GIRK4 mRNA correlates with reduced I(K,ACh) and muscarinic receptor-mediated shortening of action potentials. Circulation. 2001;104(21):2551\u20137. https:\/\/doi.org\/10.1161\/hc4601.099466.","journal-title":"Circulation"},{"issue":"11","key":"586_CR52","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1021\/acs.jnatprod.8b00500","volume":"81","author":"N Kusz","year":"2018","unstructured":"Kusz N, Orvos P, Bereczki L, et al. Diterpenoids from euphorbia dulcis with potassium ion channel inhibitory activity with selective G Protein-Activated inwardly rectifying ion channel (GIRK) blocking effect. J Nat Prod. 2018;81(11):2483\u201392. https:\/\/doi.org\/10.1021\/acs.jnatprod.8b00500.","journal-title":"J Nat Prod"},{"issue":"8","key":"586_CR53","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1021\/acs.jnatprod.6b00260","volume":"79","author":"A Vasas","year":"2016","unstructured":"Vasas A, Forgo P, Orvos P, et al. Myrsinane, Premyrsinane, and Cyclomyrsinane diterpenes from euphorbia falcata as potassium ion channel inhibitors with selective G Protein-Activated inwardly rectifying ion channel (GIRK) blocking effects. J Nat Prod. 2016;79(8):1990\u20132004. https:\/\/doi.org\/10.1021\/acs.jnatprod.6b00260.","journal-title":"J Nat Prod"},{"issue":"23 Suppl 2","key":"586_CR54","doi-asserted-by":"publisher","first-page":"ii14","DOI":"10.1093\/europace\/euaa426","volume":"23","author":"J Heijman","year":"2021","unstructured":"Heijman J, Hohnloser SH, Camm AJ. Antiarrhythmic drugs for atrial fibrillation: lessons from the past and opportunities for the future. Europace. 2021;23(23 Suppl 2):ii14\u201322. https:\/\/doi.org\/10.1093\/europace\/euaa426.","journal-title":"Europace"},{"issue":"6","key":"586_CR55","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1161\/01.res.73.6.1061","volume":"73","author":"Z Wang","year":"1993","unstructured":"Wang Z, Fermini B, Nattel S. Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K\u2009+\u2009current similar to Kv1.5 cloned channel currents. Circ Res. 1993;73(6):1061\u201376. https:\/\/doi.org\/10.1161\/01.res.73.6.1061.","journal-title":"Circ Res"},{"issue":"11","key":"586_CR56","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1517\/13543776.12.11.1589","volume":"12","author":"J Brendel","year":"2002","unstructured":"Brendel J, Peukert S. Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias. Expert Opin Ther Pat. 2002;12(11):1589\u201398. https:\/\/doi.org\/10.1517\/13543776.12.11.1589.","journal-title":"Expert Opin Ther Pat"},{"issue":"8","key":"586_CR57","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.biotechadv.2015.08.001","volume":"33","author":"AG Atanasov","year":"2015","unstructured":"Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, et al. Discovery and resupply of Pharmacologically active plant-derived natural products: A review. Biotechnol Adv. 2015;33(8):1582\u2013614. https:\/\/doi.org\/10.1016\/j.biotechadv.2015.08.001.","journal-title":"Biotechnol Adv"},{"issue":"6","key":"586_CR58","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1016\/j.bbagen.2013.02.008","volume":"1830","author":"GM Cragg","year":"2013","unstructured":"Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta. 2013;1830(6):3670\u201395. https:\/\/doi.org\/10.1016\/j.bbagen.2013.02.008.","journal-title":"Biochim Biophys Acta"},{"key":"586_CR59","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3389\/fphar.2020.00397","volume":"11","author":"E Lautie","year":"2020","unstructured":"Lautie E, Russo O, Ducrot P, et al. Unraveling plant natural chemical diversity for drug discovery purposes. Front Pharmacol. 2020;11:397. https:\/\/doi.org\/10.3389\/fphar.2020.00397.","journal-title":"Front Pharmacol"},{"issue":"18","key":"586_CR60","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1055\/s-0033-1351016","volume":"79","author":"I Lajter","year":"2013","unstructured":"Lajter I, Vasas A, Orvos P, et al. Inhibition of G protein-activated inwardly rectifying K\u2009+\u2009channels by extracts of polygonum persicaria and isolation of new flavonoids from the chloroform extract of the herb. Planta Med. 2013;79(18):1736\u201341. https:\/\/doi.org\/10.1055\/s-0033-1351016.","journal-title":"Planta Med"},{"key":"586_CR61","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ijcard.2016.01.016","volume":"207","author":"D Hu","year":"2016","unstructured":"Hu D, Barajas-Martinez H, Burashnikov A, et al. Mechanisms underlying atrial-selective block of sodium channels by Wenxin keli: experimental and theoretical analysis. Int J Cardiol. 2016;207:326\u201334. https:\/\/doi.org\/10.1016\/j.ijcard.2016.01.016.","journal-title":"Int J Cardiol"},{"issue":"4","key":"586_CR62","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1517\/13543780902762850","volume":"18","author":"J Tamargo","year":"2009","unstructured":"Tamargo J, Caballero R, Gomez R, et al. I(Kur)\/Kv1.5 channel blockers for the treatment of atrial fibrillation. Expert Opin Investig Drugs. 2009;18(4):399\u2013416. https:\/\/doi.org\/10.1517\/13543780902762850.","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"586_CR63","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1161\/CIRCULATIONAHA.111.075432","volume":"125","author":"T Kato","year":"2012","unstructured":"Kato T, Iwasaki YK, Nattel S. Connexins and atrial fibrillation: filling in the gaps. Circulation. 2012;125(2):203\u20136. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.075432.","journal-title":"Circulation"},{"issue":"2","key":"586_CR64","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1006\/jsbi.1998.3972","volume":"121","author":"M Yeager","year":"1998","unstructured":"Yeager M. Structure of cardiac gap junction intercellular channels. J Struct Biol. 1998;121(2):231\u201345. https:\/\/doi.org\/10.1006\/jsbi.1998.3972.","journal-title":"J Struct Biol"},{"issue":"2","key":"586_CR65","doi-asserted-by":"publisher","first-page":"65","DOI":"10.15420\/aer.2021.07","volume":"10","author":"A Kotalczyk","year":"2021","unstructured":"Kotalczyk A, Lip GY, Calkins H. The 2020 ESC guidelines on the diagnosis and management of atrial fibrillation. Arrhythm Electrophysiol Rev. 2021;10(2):65\u20137. https:\/\/doi.org\/10.15420\/aer.2021.07.","journal-title":"Arrhythm Electrophysiol Rev"},{"issue":"3","key":"586_CR66","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/europace\/eur002","volume":"13","author":"I Savelieva","year":"2011","unstructured":"Savelieva I, Kakouros N, Kourliouros A, et al. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European society of cardiology guidelines. Part I: primary prevention. Europace. 2011;13(3):308\u201328. https:\/\/doi.org\/10.1093\/europace\/eur002.","journal-title":"Europace"},{"issue":"6","key":"586_CR67","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00210-003-0834-0","volume":"368","author":"D Caouette","year":"2003","unstructured":"Caouette D, Dongmo C, Berube J, et al. Hydrogen peroxide modulates the Kv1.5 channel expressed in a mammalian cell line. Naunyn Schmiedebergs Arch Pharmacol. 2003;368(6):479\u201386. https:\/\/doi.org\/10.1007\/s00210-003-0834-0.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-025-00586-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-025-00586-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-025-00586-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:05:44Z","timestamp":1780113944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-025-00586-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["586"],"URL":"https:\/\/doi.org\/10.1007\/s40199-025-00586-7","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"20 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"13"}}